指南与共识脊柱关节炎其他结缔组织病

欧洲抗风湿病联盟(EULAR)银屑病关节炎药物治疗管理建议:2023年更新

EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update.
指南 / 共识 · Ann Rheum Dis · 2024-05-15

该更新基于系统文献综述与36名国际专家共识会议,提出7项总体原则和11条推荐,涵盖外周关节炎、中轴/附着点病、皮肤银屑病及合并症的药物选择策略,并涉及药物转换与持续缓解减量。

要点

  • 非甾体抗炎药仅推荐单药用于轻度银屑病关节炎短期治疗,口服糖皮质激素不推荐。
  • 外周关节炎推荐快速启用传统合成改善病情抗风湿药,首选甲氨蝶呤;未达标则启用生物制剂,作用机制无优先。
  • Janus激酶抑制剂主要建议在生物制剂失败后或生物制剂不适用时使用,需考虑相关危险因素。

核心结论

  • 更新建议整合现有药物,以实用且渐进的方式帮助银屑病关节炎的药物治疗管理。

研究设计与样本

  • 按照EULAR标准化操作流程,包括系统文献综述和2023年4月36名国际专家的共识会议,并确定证据水平和推荐等级。

主要发现

  • 更新建议包括7项总体原则和11条推荐,并提供药物治疗策略。
  • 非甾体抗炎药应仅用于轻度银屑病关节炎的单药短期治疗;口服糖皮质激素不推荐。
  • 外周关节炎患者推荐快速启用传统合成改善病情抗风湿药,首选甲氨蝶呤;未达治疗目标则启用生物制剂,作用机制无优先。
  • 相关皮肤银屑病应导向靶向白介素(IL)-23p40、IL-23p19、IL-17A和IL-17A/F抑制剂的生物制剂。
  • 以中轴或附着点病变为主时也提出算法;Janus激酶抑制剂主要建议在生物制剂失败后或生物制剂不适用时使用,需考虑相关危险因素。

关键数值与推荐

  • 非甾体抗炎药应仅用于轻度银屑病关节炎的单药短期治疗。
  • 口服糖皮质激素不推荐。
  • 外周关节炎推荐快速启用传统合成改善病情抗风湿药,首选甲氨蝶呤。
  • 未达治疗目标则启用生物制剂,作用机制无优先。
  • 相关皮肤银屑病应导向靶向IL-23p40、IL-23p19、IL-17A和IL-17A/F抑制剂的生物制剂。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: New modes of action and more data on the efficacy and safety of existing drugs in psoriatic arthritis (PsA) required an update of the EULAR 2019 recommendations for the pharmacological treatment of PsA. METHODS: Following EULAR standardised operating procedures, the process included a systematic literature review and a consensus meeting of 36 international experts in April 2023. Levels of evidence and grades of recommendations were determined. RESULTS: The updated recommendations comprise 7 overarching principles and 11 recommendations, and provide a treatment strategy for pharmacological therapies. Non-steroidal anti-inflammatory drugs should be used in monotherapy only for mild PsA and in the short term; oral glucocorticoids are not recommended. In patients with peripheral arthritis, rapid initiation of conventional synthetic disease-modifying antirheumatic drugs is recommended and methotrexate preferred. If the treatment target is not achieved with this strategy, a biological disease-modifying antirheumatic drug (bDMARD) should be initiated, without preference among modes of action. Relevant skin psoriasis should orient towards bDMARDs targeting interleukin (IL)-23p40, IL-23p19, IL-17A and IL-17A/F inhibitors. In case of predominant axial or entheseal disease, an algorithm is also proposed. Use of Janus kinase inhibitors is proposed primarily after bDMARD failure, taking relevant risk factors into account, or in case bDMARDs are not an appropriate choice. Inflammatory bowel disease and uveitis, if present, should influence drug choices, with monoclonal tumour necrosis factor inhibitors proposed. Drug switches and tapering in sustained remission are also addressed. CONCLUSION: These updated recommendations integrate all currently available drugs in a practical and progressive approach, which will be helpful in the pharmacological management of PsA.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Gossec L, Kerschbaumer A, Ferreira RJO, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update. Ann Rheum Dis. 2024. PMID: 38499325. doi:10.1136/ard-2024-225531

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。